OncLive SOSS

My Treatment Approach: Recent Advances in the Treatment of Multiple Myeloma in Early Relapse - Episode 5

Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

September 1, 2022

Brea Lipe, MD, Peter Forsberg, MD

Oncologists debate which patient populations most benefit from isatuximab plus carfilzomib and dexamethasone.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Patient Profile 1: A 63-Year-Old Female with Relapsed Multiple Myeloma

EP. 2: Treatment Options for Patients with Multiple Myeloma in Early Relapse

EP. 3: IKEMA Trial of Isatuximab plus Carfilzomib and Dexamethasone in R/R MM

EP. 4: Clinical Implications of the IKEMA Trial in R/R MM

EP. 5: Selecting the Appropriate Patients With MM for Treatment With Isa-Kd

EP. 6: Treatment of Patients With MM and High-Risk Cytogenetics

EP. 7: Patient Profile 2: A 76-Year-Old Female with R/R MM

EP. 8: CANDOR Trial of Daratumumab Plus Carfilzomib and Dexamethasone in R/R MM

EP. 9: Selecting Patients for Treatment With DARA-Kd

EP. 10: Sequencing Therapies in Patients With R/R MM

EP. 11: Advice for Community Oncologists Treating Patients With R/R MM

x